Spruce Biosciences (SPRB) Short term Debt (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Short term Debt of $1.0 million for Q1 2026, down 25.65% year-over-year from $1.3 million in Q1 2025, and up 85.53% quarter-over-quarter from $539000.0 in Q3 2025.
Spruce Biosciences (SPRB) Short term Debt (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Short term Debt for 7 consecutive years, with $1.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Short term Debt fell 25.65% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $1.0 million (down 25.65% YoY), while the FY2024 annual figure was $1.6 million, changed 0.0% from the prior year.
- Short term Debt improved to $1.0 million in Q1 2026 per SPRB's latest filing, from $539000.0 in the prior quarter.
- Across five years, Short term Debt topped out at $1.6 million in Q4 2022 and bottomed at $405000.0 in Q1 2022.
- Historically, Short term Debt has averaged $1.3 million across 5 years, with a median of $1.6 million in 2022.
- Annual changes were most pronounced in 2023 — Short term Debt jumped 300.49% — and 2025, when it tumbled 66.77%.
- Spruce Biosciences' Short term Debt stood at $1.6 million in 2022, then changed by 0.0% to $1.6 million in 2023, then changed by 0.0% to $1.6 million in 2024, then sank by 66.77% to $539000.0 in 2025, then jumped by 85.53% to $1.0 million in 2026.
- Business Quant data shows SPRB's Short term Debt at $1.0 million in Q1 2026, $539000.0 in Q3 2025, and $943000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Spruce Biosciences | 127.07 Mn | 127.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.50 Mn |
| Mar 31, 2026 | 1.00 Mn |
| Sep 30, 2025 | 539,000.00 |
| Jun 30, 2025 | 943,000.00 |
| Mar 31, 2025 | 1.35 Mn |
| Dec 31, 2024 | 1.62 Mn |
| Sep 30, 2024 | 1.62 Mn |
| Jun 30, 2024 | 1.62 Mn |
| Mar 31, 2024 | 1.62 Mn |
| Dec 31, 2023 | 1.62 Mn |
| Sep 30, 2023 | 1.62 Mn |
| Jun 30, 2023 | 1.62 Mn |
| Mar 31, 2023 | 1.62 Mn |
| Dec 31, 2022 | 1.62 Mn |
| Sep 30, 2022 | 1.22 Mn |
| Jun 30, 2022 | 811,000.00 |
| Mar 31, 2022 | 405,000.00 |
| Dec 31, 2020 | 2.55 Mn |
| Sep 30, 2020 | 1.91 Mn |
| Dec 31, 2019 | 1.25 Mn |